Instrument Inactif

Autres langues Clementia Pharmaceuticals Inc

Actions

CA1855751071

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.	11/04/19
Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.	09/04/19
WeissLaw LLP Investigates Clementia Pharmaceuticals, Inc.	01/03/19
Trade tariff reprieve triggers relief in European shares	25/02/19
GLOBAL MARKETS LIVE: Roche, AT&T, Spotify, General Electric…	25/02/19
Clementia Pharmaceuticals : Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion	25/02/19
Clementia Announces Date of Fourth Quarter and Full Year 2018 Results and Presentation at 8th Annual SVB Leerink Global Healthcare Conference	20/02/19
Clementia Announces the Departure of Chief Commercial Officer	30/11/18
Clementia to Present at the Evercore ISI HealthCONx Conference	21/11/18
Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates	07/11/18
Clementia Announces Pricing of Public Offering of Common Shares	30/10/18
Clementia Announces Proposed Public Offering of Common Shares	29/10/18
Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results	23/10/18
Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers	02/10/18
Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP	26/09/18
Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences	05/09/18
Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP	16/08/18
Clementia Reports Second Quarter 2018 Operating Results and Pipeline Updates	09/08/18
Clementia to Present at the Jefferies 2018 Global Healthcare Conference	31/05/18
Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP	23/05/18

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Clementia Pharmaceuticals Inc

Actions

CA1855751071

Autres langues

Filtres